EN
The presented studies were concentrated on construction of the recombinant mammalian expression vector - pSecTag2B, carrying canine parvovirus VP2 gene and its N-terminal fragment. Evaluation of safety of experimental vaccines was done on laboratory animals and immunogenic properties were tested on dogs. CPV specific antibodies were not detected by HI test in serum samples collected from dogs vaccinated with recombinant plasmid pSecTag2B-CPV582. The presence of CPV specific antibodies (80-320 by HI) was confirmed 10 days after vaccination in all dogs vaccinated with pSecTag2B-CPV1774. The highest titre was obtained in sera collected from dogs vaccinated with 200 μg and 300 μg of DNA. Fourteen days after revaccination, the level of antibodies increased up to 160 in dogs vaccinated with 100 μg of DNA and up to 640 in puppies vaccinated with 200 μg and 300 μg of DNA. The antibodies were detected for at least 16 weeks. Results of the studies demonstrated the immunogenic properties of elaborated DNA vaccine.